Details of the Drug

General Information of Drug (ID: DMKB79O)

• Drug Name: Bromfenac
• Synonyms: Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Postoperative inflammation	1A00-CA43.1	Approved	[1], [2]
Inflammation	1A00-CA43.1	Withdrawn from market	[1], [3]

• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 334.16
  Topological Polar Surface Area (xlogp); 3.3
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Bioavailability: 67% of drug becomes completely available to its intended biological destination(s) [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.3 mL/min/kg [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.6 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.275 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.0011% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.11 L/kg [6]
• Chemical Identifiers:
  Formula: C15H12BrNO3
  IUPAC Name: 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
  Canonical SMILES: C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
  InChI: InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
  InChIKey: ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 60726
  ChEBI ID: CHEBI:240107
  CAS Number: 91714-94-2
  DrugBank ID: DB00963
  TTD ID: D0U1OM
  VARIDT ID: DR01332
  INTEDE ID: DR1765

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[10]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[10]

Molecular Expression Atlas of This Drug

• The Studied Disease: Postoperative inflammation
• ICD Disease Classification: 1A00-CA43.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 1 (COX-1)	DTT	PTGS1	3.97E-03	0.16	0.43
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	8.15E-01	6.20E-03	5.61E-02
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bromfenac (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[58]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Bromfenac and Glibenclamide.	Acute diabete complication [5A2Y]	[59]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Bromfenac and Glipizide.	Acute diabete complication [5A2Y]	[59]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Bromfenac and Inotersen.	Amyloidosis [5D00]	[60]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[61]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Bromfenac and Cilostazol.	Arterial occlusive disease [BD40]	[62]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Bromfenac and Budesonide.	Asthma [CA23]	[63]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Bromfenac and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[64]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Kanamycin.	Bacterial infection [1A00-1C4Z]	[65]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Streptomycin.	Bacterial infection [1A00-1C4Z]	[65]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Bromfenac and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[64]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Bromfenac and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[66]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Bromfenac and ABT-492.	Bacterial infection [1A00-1C4Z]	[64]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Bromfenac and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[64]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Etidronic acid.	Bone paget disease [FB85]	[67]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bromfenac and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[68]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Bromfenac and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[62]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Bromfenac and Levomilnacipran.	Chronic pain [MG30]	[69]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Bromfenac and Anisindione.	Coagulation defect [3B10]	[62]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Bromfenac and Regorafenib.	Colorectal cancer [2B91]	[60]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Bromfenac and Drospirenone.	Contraceptive management [QA21]	[70]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Bromfenac and Ardeparin.	Coronary thrombosis [BA43]	[71]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Bromfenac and Danaparoid.	Deep vein thrombosis [BD71]	[62]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Bromfenac and Rivaroxaban.	Deep vein thrombosis [BD71]	[72]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Bromfenac and Sertraline.	Depression [6A70-6A7Z]	[69]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Bromfenac and Vilazodone.	Depression [6A70-6A7Z]	[69]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Bromfenac and Vortioxetine.	Depression [6A70-6A7Z]	[69]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Bromfenac and Milnacipran.	Depression [6A70-6A7Z]	[69]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Bromfenac and Escitalopram.	Depression [6A70-6A7Z]	[69]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Bromfenac and Desvenlafaxine.	Depression [6A70-6A7Z]	[69]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Bromfenac and Clomipramine.	Depression [6A70-6A7Z]	[69]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Cannabidiol.	Epileptic encephalopathy [8A62]	[60]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Bromfenac and Tazemetostat.	Follicular lymphoma [2A80]	[62]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Bromfenac and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[60]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Bromfenac and Sulfinpyrazone.	Gout [FA25]	[62]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[73]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Bromfenac and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[74]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Bromfenac and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[75]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Bromfenac and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[76]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Bromfenac when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[77]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Bromfenac and Dipyridamole.	Hypertension [BA00-BA04]	[62]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Balsalazide.	Indeterminate colitis [DD72]	[78]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Bromfenac and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[79]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Idelalisib.	Mature B-cell leukaemia [2A82]	[80]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Bromfenac and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[81]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Bromfenac and Ibrutinib.	Mature B-cell lymphoma [2A85]	[82]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Bromfenac and Ponatinib.	Mature B-cell lymphoma [2A85]	[83]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Bromfenac and Exjade.	Mineral absorption/transport disorder [5C64]	[84]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Bromfenac and Panobinostat.	Multiple myeloma [2A83]	[58]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Bromfenac and Deflazacort.	Muscular dystrophy [8C70]	[63]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Bromfenac and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[62]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Bromfenac and Dasatinib.	Myeloproliferative neoplasm [2A20]	[85]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Bromfenac and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[86]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Bromfenac and Prasugrel.	Myocardial infarction [BA41-BA43]	[60]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Bromfenac and Vorapaxar.	Myocardial infarction [BA41-BA43]	[87]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Bromfenac and Sibutramine.	Obesity [5B80-5B81]	[88]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Bromfenac when combined with Polythiazide.	Oedema [MG29]	[89]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Bromfenac and MK-4827.	Ovarian cancer [2C73]	[60]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Bromfenac and Epoprostenol.	Pulmonary hypertension [BB01]	[90]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Bromfenac and Iloprost.	Pulmonary hypertension [BB01]	[90]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Bromfenac and Everolimus.	Renal cell carcinoma [2C90]	[91]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Bromfenac and Temsirolimus.	Renal cell carcinoma [2C90]	[91]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Bromfenac and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[66]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Bromfenac and Dexamethasone.	Rheumatoid arthritis [FA20]	[63]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Bromfenac and Leflunomide.	Rheumatoid arthritis [FA20]	[75]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bromfenac and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[60]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Bromfenac and Pitolisant.	Somnolence [MG42]	[60]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Bromfenac and Plicamycin.	Testicular cancer [2C80]	[62]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Bromfenac and Caplacizumab.	Thrombocytopenia [3B64]	[62]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Bromfenac and Apixaban.	Thrombosis [DB61-GB90]	[60]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Bromfenac and Cangrelor.	Thrombosis [DB61-GB90]	[62]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Bromfenac and Brilinta.	Thrombosis [DB61-GB90]	[60]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Bromfenac and Cabozantinib.	Thyroid cancer [2D10]	[92]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Bromfenac and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[93]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Olsalazine.	Ulcerative colitis [DD71]	[78]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Bromfenac and Plazomicin.	Urinary tract infection [GC08]	[94]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Bromfenac and Betrixaban.	Venous thromboembolism [BD72]	[95]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7131).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021664.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [5] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [9] Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
• [10] Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
• [11] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [12] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [13] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [14] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [15] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [16] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [17] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [18] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [19] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [20] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [21] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [22] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [23] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [24] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [25] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [26] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [27] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [28] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [29] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [30] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [31] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [32] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [33] Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
• [34] Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
• [35] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [36] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [37] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [38] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [39] Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
• [40] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [41] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [42] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [43] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [44] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [45] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [46] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [47] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [48] FDA Drug Development and Drug Interactions
• [49] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [50] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [51] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [52] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [53] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [54] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [55] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [56] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [57] Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
• [58] Cerner Multum, Inc. "Australian Product Information.".
• [59] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [60] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [61] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [62] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [63] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
• [64] Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
• [65] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
• [66] Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
• [67] Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
• [68] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [69] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [70] Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
• [71] Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
• [72] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [73] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [74] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [75] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
• [76] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [77] McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
• [78] Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
• [79] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
• [80] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [81] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [82] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [83] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [84] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [85] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [86] Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
• [87] Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
• [88] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
• [89] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
• [90] Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
• [91] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [92] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [93] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
• [94] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
• [95] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]